[96a5a0]: / output / allTrials / identified / NCT00815620_identified.json

Download this file

270 lines (270 with data), 10.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
{
"info": {
"nct_id": "NCT00815620",
"official_title": "Best Therapy for Patients With Neuroendocrine Tumors",
"inclusion_criteria": "* Biopsy-proven neuroendocrine tumor (WHO class I-II, TNM grading 1-2)\n* Advanced disease with lymph node or distant metastases (N1, M1) undergoing cytoreduction by surgery/local ablative therapy or peptide receptor radiotherapy\n* curative intent of all therapies possible\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 90 Years",
"exclusion_criteria": "* Undifferentiated neuroendocrine carcinoma (WHO class III, TNM grading 3)\n* secondary tumor\n* advanced carcinoid heart disease requiring surgery",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Biopsy-proven neuroendocrine tumor (WHO class I-II, TNM grading 1-2)",
"criterions": [
{
"exact_snippets": "Biopsy-proven neuroendocrine tumor",
"criterion": "neuroendocrine tumor",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "biopsy-proven"
}
]
},
{
"exact_snippets": "WHO class I-II",
"criterion": "WHO class",
"requirements": [
{
"requirement_type": "classification",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "TNM grading 1-2",
"criterion": "TNM grading",
"requirements": [
{
"requirement_type": "grading",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Advanced disease with lymph node or distant metastases (N1, M1) undergoing cytoreduction by surgery/local ablative therapy or peptide receptor radiotherapy",
"criterions": [
{
"exact_snippets": "Advanced disease with lymph node or distant metastases (N1, M1)",
"criterion": "disease stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"N1",
"M1"
]
}
]
},
{
"exact_snippets": "undergoing cytoreduction by surgery/local ablative therapy",
"criterion": "cytoreduction treatment",
"requirements": [
{
"requirement_type": "treatment type",
"expected_value": [
"surgery",
"local ablative therapy"
]
}
]
},
{
"exact_snippets": "undergoing ... peptide receptor radiotherapy",
"criterion": "peptide receptor radiotherapy",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": true
}
]
}
]
},
{
"line": "* curative intent of all therapies possible",
"criterions": [
{
"exact_snippets": "curative intent of all therapies possible",
"criterion": "therapies",
"requirements": [
{
"requirement_type": "intent",
"expected_value": "curative"
},
{
"requirement_type": "possibility",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 90 Years",
"criterions": [
{
"exact_snippets": "maximum age of 90 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 90,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Undifferentiated neuroendocrine carcinoma (WHO class III, TNM grading 3)",
"criterions": [
{
"exact_snippets": "Undifferentiated neuroendocrine carcinoma",
"criterion": "neuroendocrine carcinoma",
"requirements": [
{
"requirement_type": "differentiation",
"expected_value": "undifferentiated"
}
]
},
{
"exact_snippets": "WHO class III",
"criterion": "WHO classification",
"requirements": [
{
"requirement_type": "classification",
"expected_value": "III"
}
]
},
{
"exact_snippets": "TNM grading 3",
"criterion": "TNM grading",
"requirements": [
{
"requirement_type": "grading",
"expected_value": {
"operator": "=",
"value": 3,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* secondary tumor",
"criterions": [
{
"exact_snippets": "secondary tumor",
"criterion": "secondary tumor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* advanced carcinoid heart disease requiring surgery",
"criterions": [
{
"exact_snippets": "advanced carcinoid heart disease",
"criterion": "carcinoid heart disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "advanced"
}
]
},
{
"exact_snippets": "requiring surgery",
"criterion": "surgery requirement",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}